BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36963446)

  • 41. Use of serum KL-6 level for detecting patients with restrictive allograft syndrome after lung transplantation.
    Berastegui C; Gómez-Ollés S; Mendoza-Valderrey A; Pereira-Veiga T; Culebras M; Monforte V; Saez B; López-Meseguer M; Sintes-Permanyer H; Ruiz de Miguel V; Bravo C; Sacanell J; Ramon MA; Romero L; Deu M; Román A
    PLoS One; 2020; 15(1):e0226488. PubMed ID: 31929536
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systems prediction of chronic lung allograft dysfunction: Results and perspectives from the Cohort of Lung Transplantation and Systems prediction of Chronic Lung Allograft Dysfunction cohorts.
    Pison C; Tissot A; Bernasconi E; Royer PJ; Roux A; Koutsokera A; Coiffard B; Renaud-Picard B; Le Pavec J; Mordant P; Demant X; Villeneuve T; Mornex JF; Nemska S; Frossard N; Brugière O; Siroux V; Marsland BJ; Foureau A; Botturi K; Durand E; Pellet J; Danger R; Auffray C; Brouard S; Nicod L; Magnan A;
    Front Med (Lausanne); 2023; 10():1126697. PubMed ID: 36968829
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial.
    Gottlieb J; Verleden GM; Perchl M; Valtin C; Vallee A; Brugière O; Bravo C
    PLoS One; 2021; 16(12):e0260881. PubMed ID: 34941934
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between cytomegalovirus viremia and long-term outcomes in lung transplant recipients.
    Kawashima M; Ma J; Huszti E; Levy L; Berra G; Renaud-Picard B; Takahagi A; Ghany R; Sato M; Keshavjee S; Singer L; Husain S; Kumar D; Tikkanen J; Martinu T
    Am J Transplant; 2024 Jun; 24(6):1057-1069. PubMed ID: 38307417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ?
    Verleden SE; Ruttens D; Vandermeulen E; Vaneylen A; Dupont LJ; Van Raemdonck DE; Verleden GM; Vanaudenaerde BM; Vos R
    Transplantation; 2013 May; 95(9):1167-72. PubMed ID: 23425818
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary graft dysfunction grade 3 following pediatric lung transplantation is associated with chronic lung allograft dysfunction.
    Wong W; Johnson B; Cheng PC; Josephson MB; Maeda K; Berg RA; Kawut SM; Harhay MO; Goldfarb SB; Yehya N; Himebauch AS
    J Heart Lung Transplant; 2023 May; 42(5):669-678. PubMed ID: 36639317
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chronic lung allograft dysfunction subtype analysis by computed tomography volumetry.
    Peräkylä LH; Raivio PM; Kesävuori RI; Piilonen AK; Stark CK; Halme MK; Nykänen AI
    Clin Transplant; 2022 Jan; 36(1):e14507. PubMed ID: 34634164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bronchoalveolar lavage cytokine-based risk stratification of minimal acute rejection in clinically stable lung transplant recipients.
    Levy L; Huszti E; Ahmed M; Ghany R; Hunter S; Moshkelgosha S; Zhang CYK; Boonstra K; Klement W; Tikkanen J; Singer LG; Keshavjee S; Juvet S; Martinu T
    J Heart Lung Transplant; 2021 Dec; 40(12):1540-1549. PubMed ID: 34215500
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.
    Benden C; Haughton M; Leonard S; Huber LC
    J Heart Lung Transplant; 2017 Sep; 36(9):921-933. PubMed ID: 28662986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bronchiolitis obliterans syndrome and restrictive allograft syndrome after lung transplantation: why are there two distinct forms of chronic lung allograft dysfunction?
    Sato M
    Ann Transl Med; 2020 Mar; 8(6):418. PubMed ID: 32355862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of chronic lung allograft dysfunction, especially restrictive allograft syndrome, on the survival after living-donor lobar lung transplantation compared with cadaveric lung transplantation in adults: a single-center experience.
    Sugimoto S; Yamamoto H; Kurosaki T; Otani S; Okazaki M; Yamane M; Toyooka S; Oto T
    Surg Today; 2019 Aug; 49(8):686-693. PubMed ID: 30790054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. When tissue is the issue: A histological review of chronic lung allograft dysfunction.
    Verleden SE; Von der Thüsen J; Roux A; Brouwers ES; Braubach P; Kuehnel M; Laenger F; Jonigk D
    Am J Transplant; 2020 Oct; 20(10):2644-2651. PubMed ID: 32185874
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.
    Kulkarni HS; Cherikh WS; Chambers DC; Garcia VC; Hachem RR; Kreisel D; Puri V; Kozower BD; Byers DE; Witt CA; Alexander-Brett J; Aguilar PR; Tague LK; Furuya Y; Patterson GA; Trulock EP; Yusen RD
    J Heart Lung Transplant; 2019 Jan; 38(1):5-16. PubMed ID: 30391193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential cytokine, chemokine and growth factor expression in phenotypes of chronic lung allograft dysfunction.
    Verleden SE; Ruttens D; Vos R; Vandermeulen E; Moelants E; Mortier A; Van Raemdonck DE; Proost P; Schols D; Verleden GM; Vanaudenaerde BM
    Transplantation; 2015 Jan; 99(1):86-93. PubMed ID: 25050473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cell-Free DNA and CXCL10 Derived from Bronchoalveolar Lavage Predict Lung Transplant Survival.
    Yang JYC; Verleden SE; Zarinsefat A; Vanaudenaerde BM; Vos R; Verleden GM; Sarwal RD; Sigdel TK; Liberto JM; Damm I; Watson D; Sarwal MM
    J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30781765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lung Ultrasound to Phenotype Chronic Lung Allograft Dysfunction in Lung Transplant Recipients. A Prospective Observational Study.
    Davidsen JR; Laursen CB; Højlund M; Lund TK; Jeschke KN; Iversen M; Kalhauge A; Bendstrup E; Carlsen J; Perch M; Henriksen DP; Schultz HHL
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33807615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Type-1 immunity and endogenous immune regulators predominate in the airway transcriptome during chronic lung allograft dysfunction.
    Iasella CJ; Hoji A; Popescu I; Wei J; Snyder ME; Zhang Y; Xu W; Iouchmanov V; Koshy R; Brown M; Fung M; Langelier C; Lendermon EA; Dugger D; Shah R; Lee J; Johnson B; Golden J; Leard LE; Ellen Kleinhenz M; Kilaru S; Hays SR; Singer JP; Sanchez PG; Morrell MR; Pilewski JM; Greenland JR; Chen K; McDyer JF
    Am J Transplant; 2021 Jun; 21(6):2145-2160. PubMed ID: 33078555
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Significance of phenotype change after chronic lung allograft dysfunction onset.
    Fuchs E; Levy L; Huszti E; Renaud-Picard B; Berra G; Kawashima M; Takahagi A; Ghany R; Havlin J; McInnis MC; Keshavjee S; Singer LG; Tikkanen J; Chow CW; Martinu T
    Transpl Int; 2021 Dec; 34(12):2620-2632. PubMed ID: 34748217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronic lung allograft dysfunction phenotypes and treatment.
    Verleden SE; Vos R; Vanaudenaerde BM; Verleden GM
    J Thorac Dis; 2017 Aug; 9(8):2650-2659. PubMed ID: 28932572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients.
    DerHovanessian A; Todd JL; Zhang A; Li N; Mayalall A; Finlen Copeland CA; Shino M; Pavlisko EN; Wallace WD; Gregson A; Ross DJ; Saggar R; Lynch JP; Belperio J; Snyder LD; Palmer SM; Weigt SS
    Ann Am Thorac Soc; 2016 May; 13(5):627-35. PubMed ID: 27144793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.